600% Kurspotential YM Biosciences 911799

he Best Investing Ideas in Health Care
By Motley Fool Staff
July 12, 2010 | Comments (0)

Recs
3

Email
 Share
Print
TRUE
Centrue Financia
Rate TRUE
CAPS Rating 0/5 Stars
$2.05 $0.00 (0.00%)

Netflix Hits $100!
David Gardner called Netflix in 2004 at $15.42. He’s up 546% as of April 23rd. See what David’s recommending that you buy NEXT.
Click Here Now
Chasing highfliers is a sucker's game. But tracking monthly trends across the market can lead to great investment ideas, while shedding new light on stocks you already have in your portfolio.

Let's take a look at the biggest movers in health care. These stocks -- which include companies from the pharmaceutical and biotechnology sectors -- have clocked some of the biggest gains during the last month.

Health-care market movers

Company
Industry
CAPS Rating
30-Day Return
Market Cap
Price / Earnings
Biovail (NYSE: BVF)
Pharmaceuticals
***
31.78%
3.04B
29.16
Arena Pharmaceuticals (Nasdaq: ARNA)
Biotechnology
***
29.83%
381.73M
N/A
AVANIR Pharmaceuticals (Nasdaq: AVNR)
Pharmaceuticals
****
22.51%
309.17M
13
Neurocrine Biosciences (Nasdaq: NBIX)
Biotechnology
**
22.41%
305.96M
91.67
Those returns are certainly eye-catching. But do these highfliers have staying power?

Let's see what The Motley Fool CAPS community (more than 165,000 investors strong) has to say about the best plays in the health-care market.

And the next big winners are ...

YM BioSciences granted Orphan Drug Designation for CYT387

-JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis-
MISSISSAUGA, ON, Aug. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.
Orphan Drug Designation is granted to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity upon marketing approval for the designated indication, as well as with tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees.
"CYT387 is a potent, oral JAK1/2 inhibitor that has been demonstrating very favorable biological activity data in our ongoing Phase I/II trial in myelofibrosis and the granting of Orphan Drug Designation is a key regulatory milestone for our CYT387 clinical development program," said Dr. Nick Glover, COO of YM BioSciences. "This event provides us with further support for our expanding commitment to this promising drug as we continue to broaden our investment in our CYT387 development program while concentrating on advancing the molecule towards an NDA-enabling study in myelofibrosis."